Schiffer, L., Sharifi, N. Adrenal-Permissive HSD3B1 Genotype-An Invisible Stimulator of Prostate Cancer Mortality. JAMA Netw Open. Mar. 2024. DOI: 10.1001/jamanetworkopen.2024.3402

Qin, L., Berk, M., Chung, Y-M., Cui, D., Zhu, Z., Chakraborty, A., Sharifi, N. Chronic hypoxia stabilizes 3βHSD1 via autophagy suppression. Cell Reports. Jan 2024. DOI: 10.1016/j.celrep.2023.113575

Ganguly, S., Lone, Z., Muskara, A., Imamura, J., Hardaway, A., Patel, M., Berk, M., Smile, T., Davicioni, E., Stephans, K., Ciezki, J., Weight, C., Gupta, S., Reddy, C., Tendulkar, R., Chakraborty, A., Klein, E., Sharifi, N., Mian, O. Intratumoral androgen biosynthesis associated with 3β-hydroxysteroid dehydrogenase 1 promotes resistance to radiotherapy in prostate cancer. J Clin Invest. Nov 2023. DOI: 10.1172/JCI165718

Alyamani, M., Michael, P., Hettel, D., Thomas, L., Lundy, S., Berk, M., Patel, M., Li, J., Rashidi, H., McKenney, J., Klein, E., Sharifi, N. Elevated periprostatic venous testosterone correlates with prostate cancer progression after radical prostatectomy. J Clin Invest. Sept 2023. DOI: 10.1172/JCI171117

Dai, C., Dehm, S.M., Sharifi, N. Targeting the androgen signaling axis in prostate cancer. J Clin Oncol. July 2023. DOI: 10.1200/JCO.23.00433

Cui, D., Li, J., Zhu, Z., Berk, M., Hardaway, A., McManus, J., Chung, Y-M., Alyamani, M., Valle, S., Tiwari, R., Han, B., Goudarzi, M., Willard, B., Sharifi, N. Cancer-associated fibroblast-secreted glucosamine alters the androgen biosynthesis program in prostate cancer via HSD3B1 upregulation. J Clin Invest. April 2023. DOI: 10.1172/JCI161913

Li, X., Berk, M., Goins, C., Alyamani, M., Chung, Y-M., Wang, C., Patel, M., Rathi, N., Zhu, Z., Willard, B., Stauffer, S., Klein, E.A., Sharifi, N. BMX controls 3βHSD1 and sex steroid biosynthesis in cancer. J Clin Invest. Jan 2023. DOI: 10.1172/JCI163498

Hardaway AL, Goudarzi M, Berk M, Chung YM, Zhang R, Li J, Klein E, Sharifi N. 5-Hydroxyeicosatetraenoic Acid Controls Androgen Reduction in Diverse Types of Human Epithelial Cells. Endocrinology. Nov 2022. DOI: 10.1210/endocr/bqac191

Flanagan, M.R., Doody, D.R., Voutsinas, J., Wu, Q., Banda, K., Sharifi, N., Li, C.I., Gadi, V. Association of HSD3B1 genotype and clinical outcomes in postmenopausal estrogen-receptor positive breast cancer. Annals Surg Oncol. Oct 2022. DOI: 10.1245/s10434-022-12411-5

Baratchian, M, Tiwari, R, Khalighi, S., Chakravarthy, A, Yuan, W, Berk, M, Li, J, Guerinot, A, de Bono, J, Makarov, V, Chan, TA, Silverman, RH, Stark, GR, Varadan, V, De Carvalho, D, Chakraborty, AA, Sharifi, N. H3K9 methylation drives resistance to AR-antagonist therapy in prostate cancer. Proc Natl Acad Sci USA. May 2022. DOI: 10.1073/pnas.2114324119

Li, J, Berk, M, Alyamani, M, Sabharwal, N, Goins, G, Alvarado, J, Baratchian, M, Zhu, Z, Stauffer, S, Klein, EA, Sharifi, N. Hexose-6-phosphate dehydrogenase blockade reverses prostate cancer drug resistance in xenograft models by glucocorticoid inactivation. Sci Transl Med. May 2021. DOI: 10.1126/scitranslmed.abe8226

Baratchian, M., McManus, J.M., Berk, M., Nakamura, F., Mukhopadhyay, S., Xu, W., Erzurum, S., Drazba, J., Peterson, J., Klein, E.A., Gaston, B., Sharifi, N. Sex, androgens and regulation of pulmonary AR, TMPRSS2 and ACE2. Sci Rep. May 2021. DOI: 10.1038/s41598-021-90491-1

Desai, K, McManus, J, Sharifi, N. Hormonal therapy for prostate cancer. Endocr Rev. Jun 2021. DOI: 10.1210/endrev/bnab002

Sharifi, N. Kicking the dirt in the hunt for discoveries: pursuing a career in biomedical science. Nature Rev Urol. Feb 2021. DOI: 10.1038/s41585-021-00433-9

Hofmann, MR, Hussain, M, Dehm, SM, Beltran, H, Wyatt, AW, Halabi, S, Sweeney, C, Scher, HI, Ryan, CJ, Feng, FY, Attard, G, Klein, E, Miyahira, AK, Soule, HR, Sharifi, N. Prostate Cancer Foundation Hormone-Sensitive Prostate Cancer Biomarker Working Group Meeting Summary. Urology. Dec 2020. DOI: 10.1016/j.urology.2020.12.021

Thomas L and Sharifi N. Germline HSD3B1 genetics and prostate cancer outcomes. Urology. Aug 2020. DOI: 10.1016/j.urology.2020.08.028

Naelitz B and Sharifi N. Through the looking-glass: Reevaluating DHEA metabolism through HSD3B1 genetics. Trends Endocrinol Metabol. Sep 2020. DOI: 10.1016/j.tem.2020.05.006

Zein, J, Gaston, B, Bazeley, P, DeBoer, MD, Igo, RP, Bleecker, ER, Meyers, D, Comhair, S, Marozkina, NV, Cotton, C, Patel, M, Alyamani, M, Xu, W, Busse, W, Calhoun, WJ, Ortega, V, Hawkins, GA, Castro, M, Chung, KF, Fahy, JV, Fitzpatrick, AM, Israel, E, Jarjour, NN, Levy, B, Mauger, D, Moore, WC, Noel, P, Peters, SP, Teague, WG, Wenzel, SE, Erzurum, SC, Sharifi, N. HSD3B1 genotype identifies glucocorticoid responsiveness in severe asthma. Proc Natl Acad Sci USA. Jan 2020. DOI: 10.1073/pnas.1918819117

Alyamani, M, Li, J, Patel, M, Taylor, S, Nakamura, F, Berk, M, Przybycin, C, Posadas, EM, Madan, RA, Gulley, JL, Rini, B, Garcia, J, Klein, E, Sharifi, N. Deep AR suppression in prostate cancer exploits sexually dimorphic renal expression for systemic glucocorticoid exposure. Annals Oncol. Mar 2020. DOI: 10.1016/j.annonc.2019.12.002

Hearn, J, Sweeney, C, Almassi, N, Reichard, CA, Reddy, CA, Hobbs, B, Jarrard, DF, Chen, Y-H, Dreicer, R, Garcia, JA, Carducci, MA, DiPaola, RS, Sharifi, N. HSD3B1 genotype and clinical outcomes in metastatic castration-sensitive prostate cancer. JAMA Oncol. Feb 2020. DOI: 10.1001/jamaoncol.2019.6496

Zhu, Z., Chung, Y.M., Sergeeva, O., Kepe, V., Berk, M., Li, J., Ko, H-K., Li, Z., Petro, M., DiFilippo, F.P., Lee, Z., Sharifi, N. Loss of dihydrotestosterone-inactivation activity promotes prostate cancer castration resistance detectable by functional imaging. J. Biol Chem. Nov 2018. DOI: 10.1074/jbc.RA118.004846

Li, J., Alyamani, M., Zhang, A., Chang, K-H., Berk, M., Li, Z., Zhu, Z., Petro, M., Magi-Galluzzi, C., Taplin, M-E., Garcia, J.A., Courtney, K., Klein, E.A., Sharifi, N. Aberrant corticosteroid metabolism in tumor cells enables GR takeover in enzalutamide resistant prostate cancer.  eLife. Feb 2017. DOI: 10.7554/eLife.20183

Dai, C., Heemers, H., Sharifi, N. Androgen signaling in prostate cancer. Cold Spring Harb Perspect Med. Sept 2017. DOI: 10.1101/cshperspect.a030452

Hearn, J.W.D., AbuAli, G., Reichard, C.A., Reddy, C.A., Magi-Galluzzi, C., Chang, K-H., Carlson, R., Rangel, L., Reagan, K., Davis, B.J., Karnes, R.J., Kohli, M., Tindall, D., Klein, E.A., Sharifi, N. HSD3B1 and resistance to androgen deprivation therapy in prostate cancer: a multi-cohort study. Lancet Oncol. Oct 2016. DOI: 10.1016/S1470-2045(16)30227-3

Li, Z., Alyamani, M., Li, J., Upadhyay, S., Balk, S.P., Taplin, M-E., Auchus, R.J., Sharifi, N. Redirecting abiraterone metabolism to biochemically fine tune prostate cancer anti-androgen therapy.  Nature. May 2016. DOI: 10.1038/nature17954

Li, Z., Bishop, A., Alyamani, M., Garcia, J.A., Dreicer, R., Bunch, D., Liu, J., Upadhyay, S.K., Auchus, R.J., Sharifi, N. Conversion of abiraterone to D4A drives antitumor activity in prostate cancer. Nature.  Jul 2015. DOI: 10.1038/nature14406

Chang, K-H., Li, R., Kuri, B., Lotan, Y., Roehrborn, C.G., Liu, J., Vessella, R., Nelson, P., Kapur, P., Guo, X., Mirzaei, H., Auchus, R.J., Sharifi, N. A mutation in DHT synthesis in castration-resistant prostate cancer.  Cell. 2013. DOI: 10.1016/j.cell.2013.07.029

Chang, K-H, Papari-Zareei, Watumull, L, Zhao, YD, Auchus, RJ, Sharifi N. Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer. Proc Natl Acad Sci USA. Aug 2011. DOI: 10.1073/pnas.1107898108